Viewing Study NCT05374603


Ignite Creation Date: 2025-12-24 @ 7:41 PM
Ignite Modification Date: 2025-12-30 @ 2:33 PM
Study NCT ID: NCT05374603
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-27
First Post: 2022-04-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module